Digital AI in drug development: The real hurdle is implementation Web editor Nicole Raleigh speaks with Andrew Stelzer, head of business development at Unlearn.AI, about effectively implementing AI.
Digital Patients as active consumers of care: AI-driven personalisat... In a new podcast, web editor Nicole Raleigh speaks with Bill Grambley, CEO of AllazoHealth, for a conversation on leveraging AI for marketing.
Digital GenAI and the revolution of drug development Bryan Hill, life sciences chief technology officer at Cognizant, discusses how generative AI is revolutionising drug development in a new podcast.
Digital Simulated clinical trial populations and AI scalability AI might still be in the modish buzzword stage, but discussions exploring the potential for its scaling within life sciences are critical.
Digital From science fiction to reality: AI in drug development In today’s pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Isaac Bentwich, CEO and founder of Quris.AI.
Digital Seeking effective, safe treatment for all with precision dos... Modern medicine moves ever more to precision, personalised medicine, and precision dosing is critical in a world that recognises biological individuality – especially when it comes to paedi
News Bayer trial combines two top drugs for kidney disease Data from the CONFIDENCE trial shows the value of combining Bayer's Kerendia with an SGLT2 inhibitor to treat chronic kidney disease in diabetics.
